Back to top anchor

RCT budesonide-formoterol reliever therapy in moderate/severe childhood asthma

Year:
2022
Duration:
36 months
Approved budget:
$1,439,964.30
Researchers:
Professor Stuart Dalziel
,
Professor Richard Beasley
,
Associate Professor Catherine Byrnes
,
Dr David McNamara
,
Dr Irene Braithwaite
,
Dr Alex Semprini
,
Associate Professor Matire Harwood
,
Professor Mark Weatherall
,
Dr Andrew Corin
,
Dr Barney Montgomery
,
Dr Louise Fleming
,
Professor Andrew Bush
Health issue:
Respiratory/asthma
Proposal type:
Project
Lay summary
Childhood asthma is a major public health problem in New Zealand. The evidence base for the treatment of childhood asthma is considerably less than for adult asthma. In adults, treatment with a single inhaler that contains both preventer and reliever medications, used as-needed for asthma symptoms, is markedly better at reducing asthma attacks compared to the common approach of taking a reliever-only inhaler as-needed for all asthma severity. This new treatment regimen has not been studied in children with moderate and severe asthma. If comparable efficacy with as-needed preventer+reliever inhaler treatment is shown in childhood as with adult asthma, then implementation of this approach would markedly reduce the burden of asthma in children. In this randomised controlled trial, undertaken in partnership with community general practitioners, the effect of the combined budesonide+formoterol inhaler taken as-needed will be compared with salbutamol as-needed in children aged 4-11 years with moderate and severe asthma.